376 related articles for article (PubMed ID: 30985931)
21. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
22. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
Shimony S; Luskin MR
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
[TBL] [Abstract][Full Text] [Related]
23. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
Moribe T; Xu L; Tajima K; Yonemoto N
Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
[TBL] [Abstract][Full Text] [Related]
24. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
25. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast.
Jabbour EJ; Stelljes M
Target Oncol; 2024 Mar; 19(2):135-141. PubMed ID: 38457052
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
27. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M; Raffel S; Alakel N; Wäsch R; Kondakci M; Scholl S; Rank A; Hänel M; Spriewald B; Hanoun M; Martin S; Schwab K; Serve H; Reiser L; Knaden J; Pfeifer H; Marx J; Sauer T; Berdel WE; Lenz G; Brüggemann M; Gökbuget N; Wethmar K
J Clin Oncol; 2024 Jan; 42(3):273-282. PubMed ID: 37883727
[TBL] [Abstract][Full Text] [Related]
28. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Jain N; Maiti A; Ravandi F; Konopleva M; Daver N; Kadia T; Pemmaraju N; Short N; Kebriaei P; Ning J; Cortes J; Jabbour E; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):1000-1007. PubMed ID: 33991360
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
30. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
31. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
32. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
33. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Curr Hematol Malig Rep; 2018 Apr; 13(2):91-99. PubMed ID: 29423571
[TBL] [Abstract][Full Text] [Related]
34. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
Marks DI; van Oostrum I; Mueller S; Welch V; Vandendries E; Loberiza FR; Böhme S; Su Y; Stelljes M; Kantarjian HM
Cancer Med; 2019 Oct; 8(13):5959-5968. PubMed ID: 31436395
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
36. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
37. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I; Afkhami M; Yang D; Gu Z; Mokhtari S; Shahani S; Pourhassan H; Agrawal V; Koller P; Arslan S; Tomasian V; Al Malki MM; Artz A; Salhotra A; Ali H; Aribi A; Sandhu KS; Ball B; Otoukesh S; Amanam I; Becker PS; Stewart FM; Curtin P; Smith E; Telatar M; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Am J Hematol; 2023 Jun; 98(6):848-856. PubMed ID: 36880203
[TBL] [Abstract][Full Text] [Related]
38. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
39. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
40. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
